Unidad de Gestión Clínica de Medicina Interna y Especialidades Médicas, Hospital de la Serranía, Ronda, Málaga, Spain; Facultad de Medicina, Universidad de Málaga, Málaga, Spain.
Servicio de Medicina Interna, Hospital Regional Universitario de Málaga, Málaga, Spain.
Rev Clin Esp (Barc). 2023 Oct;223(8):486-492. doi: 10.1016/j.rceng.2023.07.009. Epub 2023 Jul 31.
There are limited studies analyzing hypercalcemia in hospitalized patients. Our objectives were to describe the clinical characteristics of hospitalized patients with hypercalcemia, estimate its prevalence in the hospital setting, analyze the rate of correction of hypercalcemia, and identify prognostic variables.
Observational, longitudinal, retrospective, and bicentric study. Adult patients admitted to two hospitals in Málaga (2014-2018) with a diagnosis of hypercalcemia were included. The minimum follow-up was 2 years or until death.
A total of 205 patients with hypercalcemia were included (incidence: 0.13%). The mean age (SD) was 68.2 (13.1) years, with a predominance of males (55.1%). The median (IQR) serum calcium at admission was 13.1 (11.8-14.6) mg/dl. The most common etiologies were neoplasms (75.1%), primary hyperparathyroidism, and medications (both 8.8%). The median (IQR) follow-up period was 5.1 (1.7-60.3) weeks. The most commonly used treatments were fluid therapy (86.8%), loop diuretics (70.9%), bisphosphonates (60.7%), and glucocorticoids (46.2%). The rate of correction of hypercalcemia was 65.2%, with a median (IQR) of 6 (3-10) days. The mortality rate was 81.5%. The median (95% CI) survival was 5.1 (3-7.3) weeks. Factors associated with higher mortality were advanced age, neoplastic etiology, serum calcium at admission, and failure to correct hypercalcemia.
Hypercalcemia in hospitalized patients is mainly due to neoplastic processes and is associated with high mortality. We observed a low rate of adherence to recommendations for the management of hypercalcemia.
目前针对住院患者高钙血症的研究有限。本研究旨在描述住院高钙血症患者的临床特征,评估其在医院环境中的患病率,分析高钙血症的纠正率,并确定预后变量。
这是一项观察性、纵向、回顾性、双中心研究。纳入 2014 年至 2018 年期间在马拉加两家医院因高钙血症住院的成年患者。随访时间至少为 2 年或直至死亡。
共纳入 205 例高钙血症患者(发病率:0.13%)。患者的平均(SD)年龄为 68.2(13.1)岁,男性居多(55.1%)。入院时血清钙中位数(IQR)为 13.1(11.8-14.6)mg/dl。最常见的病因是肿瘤(75.1%)、原发性甲状旁腺功能亢进症和药物(均为 8.8%)。中位(IQR)随访时间为 5.1(1.7-60.3)周。最常用的治疗方法是补液治疗(86.8%)、袢利尿剂(70.9%)、双膦酸盐(60.7%)和糖皮质激素(46.2%)。高钙血症的纠正率为 65.2%,中位数(IQR)为 6(3-10)天。死亡率为 81.5%。中位(95%CI)生存时间为 5.1(3-7.3)周。与高死亡率相关的因素是高龄、肿瘤病因、入院时血清钙水平和高钙血症纠正失败。
住院患者高钙血症主要由肿瘤引起,与高死亡率相关。我们观察到,在高钙血症的治疗管理方面,建议的治疗方法的依从性较低。